Hualan Biological Engineering Inc.
002007
Rank in Stocks
#4386
Hualan Biological Engineering Inc. operates as a biopharmaceutical company,... Hualan Biological Engineering Inc. operates as a biopharmaceutical company, specializing in the research, development, production, and commercialization of a diverse portfolio of medical products within the People's Republic of China. Its offerings span plasma-derived therapies, various viral and bacterial vaccines, recombinant proteins, and other advanced biologics. The company's extensive range of plasma products includes essential components like human albumin, a broad spectrum of human immunoglobulins (such as intravenous, rabies, hepatitis B, and tetanus formulations), and vital coagulation factors like human prothrombin complex and factor VIII. Hualan also provides specialized solutions such as lyophilized human thrombin for external use and surgical fibrin glue. In its vaccine division, Hualan offers critical immunizations, including several influenza vaccines (e.g., split virus, A H1N1, and quadrivalent forms), recombinant hepatitis B vaccine, and ACYW135 meningococcal polysaccharide vaccine. The company actively pursues strategic collaborations with key scientific organizations, most notably the Chinese Academy of Sciences, as well as other esteemed research institutes and enterprises. Established in 1992, Hualan Biological Engineering Inc. is headquartered in Xinxiang, People's Republic of China.
Share Price
$1.92
Market Cap
$3.50B
Change (1 day)
-1.39%
Change (1 year)
-19.45%
Country
CN
Trade Hualan Biological Engineering Inc. (002007)
Category
Healthcare
P/B ratio for Hualan Biological Engineering Inc. (002007)
P/B ratio as of October 2026 TTM: 2.13
According to Hualan Biological Engineering Inc. latest financial reports and stock price the company's current price-to-book ratio (TTM) is 2.13. At the end of 2024 the company had a P/B ratio of 2.59.
P/B ratio history for Hualan Biological Engineering Inc. from 2001 to 2026
P/B ratio at the end of each year
| Year | P/B Ratio | Change |
|---|---|---|
| 2026 (TTM) | 2.13 | -11.18% |
| 2025 | 2.40 | -7.39% |
| 2024 | 2.59 | -27.01% |
| 2023 | 3.55 | -10.48% |
| 2022 | 3.97 | -37.62% |
| 2021 | 6.36 | -37.60% |
| 2020 | 10.20 | 35.87% |
| 2019 | 7.51 | 49.25% |
| 2018 | 5.03 | -10.18% |
| 2017 | 5.60 | -28.94% |
| 2016 | 7.88 | 12.72% |
| 2015 | 6.99 | 22.97% |
| 2014 | 5.69 | 5.58% |
| 2013 | 5.38 | 15.44% |
| 2012 | 4.66 | -23.42% |
| 2011 | 6.09 | -52.62% |
| 2010 | 12.85 | 7.25% |
| 2009 | 11.99 | 55.58% |
| 2008 | 7.70 | -57.54% |
| 2007 | 18.15 | 186.87% |
| 2006 | 6.33 | 322.88% |
| 2005 | 1.50 | 22.78% |
| 2004 | 1.22 | -75.16% |
| 2003 | 4.90 | -27.47% |
| 2002 | 6.76 | -30.90% |
| 2001 | 9.79 | 0.00% |
P/B ratio for similar companies or competitors
| Company | P/B Ratio | P/B Ratio Difference | Country |
|---|---|---|---|
| 6.251 | 193.25% |
US
|
|
| 13.6307 | 539.46% |
US
|
|
| 4.4521 | 108.86% |
AU
|
|
| 6.3632 | 198.52% |
NL
|
|
| 3.2932 | 54.49% |
BE
|
